It has been suggested that therapeutics that selectively decrease stress hormone levels like CRFR1 (corticotropin-releasing factor receptor-1) antagonists should be tested for efficacy in slowing AD progression (Campbell et al., 2015; Justice et al., 2015; Zhang et al., 2015, 2016; Justice, 2018). The gene discussed is CRHR1; the disease is Alzheimer disease.